Spero Therapeutics Inc. (SPRO)

HC Wainwright Brokers Boost Earnings Estimates for Spero Therapeutics, Inc. (NASDAQ:SPRO)

Spero Therapeutics, Inc. (NASDAQ:SPRO – Free Report) – HC Wainwright lifted their Q2 2024 EPS estimates for Spero Therapeutics in a note issued to investors on Thursday, May 16th. HC Wainwright analyst R. Selvaraju now anticipates that the company will post earnings per share of ($0.25) for the quarter, up from their prior forecast of ($0.41). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Spero Therapeutics’ current full-year earnings is ($1.04) per share. HC Wainwright also issued estimates for Spero Therapeutics’ Q3 2024 earnings at ($0.27) EPS, Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($1.01) EPS and FY2025 earnings at ($0.87) EPS. Spero Therapeutics (NASDAQ:SPRO – Get Free Report) last posted its quarterly earnings data on Wednesday, March 13th. The company reported $0.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $1.14. The company had revenue of $73.52 million for the quarter, compared to analyst estimates of $19.40 million. Spero Therapeutics had a net margin of 21.09% and a return on equity of 35.42%. Separately, Cantor Fitzgerald reiterated an “overweight” rating on shares of Spero Therapeutics in a research note on Thursday, April 4th. Read Our Latest Research Report on SPRO Spero Therapeutics Stock Up 1.3 % SPRO opened at $1.59 on Monday. The firm has a market capitalization of $85.84 million, a P/E ratio of 3.70 and a beta of 0.62. The firm’s 50 day moving average is $1.63 and its 200-day moving average is $1.48. Spero Therapeutics has a 52-week low of $0.99 and a 52-week high of $1.94. Institutional Trading of Spero Therapeutics A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Murchinson Ltd. increased its stake in shares of Spero Therapeutics by 1.3% in the first quarter. Murchinson Ltd. now owns 873,910 shares of the company’s stock worth $1,503,000 after buying an additional 11,210 shares during the last quarter. Acadian Asset Management LLC increased its stake in shares of Spero Therapeutics by 121.8% in the first quarter. Acadian Asset Management LLC now owns 762,598 shares of the company’s stock worth $1,310,000 after buying an additional 418,742 shares during the last quarter. Vanguard Group Inc. increased its stake in shares of Spero Therapeutics by 0.6% in the first quarter. Vanguard Group Inc. now owns 1,653,432 shares of the company’s stock worth $2,844,000 after buying an additional 9,675 shares during the last quarter. Finally, ADAR1 Capital Management LLC bought a new stake in shares of Spero Therapeutics in the fourth quarter worth $1,570,000. Institutional investors own 25.60% of the company’s stock. Spero Therapeutics Company Profile (Get Free Report) Spero Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, and commercializing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include tebipenem pivoxil hydrobromide (HBr), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adults; SPR206, an intravenous-administered antibiotic against MDR Gram-negative pathogens comprising carbapenem-resistant enterobacterales (CRE), acinetobacter baumannii, and pseudomonas aeruginosa, as well as negative bacterial infections in the hospital setting; and SPR720, a novel oral antibiotic agent for the treatment of non-tuberculous mycobacterial pulmonary disease. Read More Five stocks we like better than Spero Therapeutics How to Effectively Use the MarketBeat Ratings Screener MarketBeat Week in Review – 5/13 – 5/17 3 Ways To Invest In Coffee, Other Than Drinking It Take-Two Interactive Software Offers 2nd Chance for Investors How to Know if a Stock Pays Dividends and When They Are Paid Out Deere & Company’s Q2 Report: Strong Revenue, Cautious Outlook